Krystal Biotech, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases. The Company's lead product candidate includes KB103, which is in preclinical studies to treat dystrophic epidermolysis bullosa, a genetic disease. It also develops KB104 that is in preclinical studies to treat Netherton syndrome, a severe form of ichthyosis, which is a family of genetic skin disorders.
TypePublic
HQPittsburgh, US
Founded2015
Size (employees)6 (est)
Websitekrystalbio.com
Krystal Biotech was founded in 2015 and is headquartered in Pittsburgh, US
Report incorrect company information

Viewing summary data as a guest

Sign up for free to see all data

Krystal Biotech Office Locations

Krystal Biotech has an office in Pittsburgh
Pittsburgh, US (HQ)
701 2100 Wharton St
Show all (1)
Report incorrect company information

Krystal Biotech Financials and Metrics

Krystal Biotech Revenue

USD

Net income (FY, 2016)

(1.2 m)

EBIT (FY, 2016)

(1.1 m)

Market capitalization (20-Sep-2018)

186.6 m

Closing stock price (20-Sep-2018)

17

Cash (31-Dec-2016)

1.9 m
Krystal Biotech's current market capitalization is $186.6 m.
USDFY, 2016

General and administrative expense

402 k

R&D expense

741 k

Operating expense total

1.1 m

EBIT

(1.1 m)
USDFY, 2016

Cash

1.9 m

Prepaid Expenses

246 k

Current Assets

2.2 m

PP&E

13 k
USDFY, 2016

Net Income

(1.2 m)

Depreciation and Amortization

2 k

Cash From Operating Activities

(1.3 m)

Purchases of PP&E

(15 k)
USDY, 2016

Financial Leverage

7.6 x
Show all financial metrics
Report incorrect company information

Krystal Biotech News and Updates

Krystal Biotech to Present at Upcoming B. Riley FBR and H.C. Wainwright Healthcare Investor Conferences

PITTSBURGH, Aug. 29, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech Inc., (“Krystal”) (NASDAQ: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from skin diseases, today announced that Krish S. Krishnan, chairman and chief executive office…

Krystal Biotech Announces $10 Million Private Placement with Frazier Healthcare Partners

PITTSBURGH, Aug. 16, 2018 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (Nasdaq: KRYS), a gene therapy company dedicated to developing and commercializing novel treatments for patients suffering from dermatological diseases, today announced that it has entered into a securities purchase agreement with…

Krystal Biotech Reports Second Quarter 2018 Financial Results and Provides Corporate Update

First two patients enrolled in Phase 1/2 clinical study of KB103, a first-in-class topical gene therapy for the treatment of dystrophic epidermolysis bullosa. 
Report incorrect company information

Krystal Biotech Company Life and Culture

Report incorrect company information